Saturday, 31 October 2026European Markets

AXWAY SOFTWARE Stock Bullish Momentum With A 30% Jump In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of AXWAY SOFTWARE (CAC 40: AXW.PA) jumped by a staggering 30.79% in 21 sessions from $17.05 to $22.30 at 13:56 EST on Monday, following the last session's downward trend. CAC 40 is sliding 1.34% to $7,137.10, after two sequential sessions in a row of gains.

About AXWAY SOFTWARE

Axway Software SA operates as an infrastructure software publisher in the Americas, France, rest of Europe, the Asia Pacific, and internationally. The company provides AMPLIFY, a platform that offers application integration, API management, managed file transfer, B2B-EDI integration, and digital finance solutions. It also offers specialized enterprise integration products to provide visibility, intelligence, and security throughout the digital ecosystem; counter threats before they happen; optimize business assets and resources; safeguard against risks; and improve operational performance, as well as provides managed cloud services. The company serves the automotive, banking and financial services, healthcare, insurance, life science, manufacturing and consumer packaged goods, retail, and transportation and logistics industries, as well as government and public sectors. Axway Software SA was incorporated in 2000 and is headquartered in Scottsdale, Arizona.

Earnings Per Share

As for profitability, AXWAY SOFTWARE has a trailing twelve months EPS of $0.38.

PE Ratio

AXWAY SOFTWARE has a trailing twelve months price to earnings ratio of 58.68. Meaning, the purchaser of the share is investing $58.68 for every dollar of annual earnings.

Volume

Today's last reported volume for AXWAY SOFTWARE is 4620 which is 19.63% below its average volume of 5749.

More news about AXWAY SOFTWARE (AXW.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com